Ablation Techniques, Clinical Trial, Cryoablation, Liver Neoplasms, Neoplasm Metastasis, Safety, Treatment Outcome
Conditions
Brief summary
This study will document for the safety and efficacy of image guided multi-mode precision ablation system (the combination of cryoablation and radiofrequency ablation) for the treatment of liver malignant, as well as provide the indicator of antitumor immune response for liver malignant in China.
Detailed description
Either Cryoablation or Radiofrequency Ablation has been well accepted and widely used in clinical practice for solid tumor treatments with various commercial systems. Previous studies have established that locally exerting great thermal and mechanical stress through alternating freezing and heating abruptly broke the tumor cells and micro-vasculature in situ, enabling complete damage of primary tumor. Large amount of biological stimuli was released during this process to enhance body anti-tumor immunological response. This method thus may inhibit distal metastases and increase the survival rate. The investigators hypothesized that multi-mode thermal method (the combination of cryoablation, radiofrequency ablation) might trigger a whole body anti-tumor immune response for malignant tumor basing on multi-scale bio-thermal responses at molecular, cellular, tumor angiogenesis and tissue levels. The purpose of this study was to prospectively investigate the safety and feasibility of multi-mode precision ablation system for the treatment of liver malignant.
Interventions
DEVICEMulti-modal Precision Ablation
In Multi-modal Precision Ablation group, patients received Image-guided cryoablation immediately followed by radiofrequency ablation
Sponsors
Fudan University
Ruijin Hospital
Changhai Hospital
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Shanghai Zhongshan Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* 1.Adults aged 18 years to 70 years of either gender; * 2\. Histologically/cytologically confirmed hepatocellular carcinoma or colorectal cancer with liver metastasis, the primary lesion had underwent radical resection and without local recurrent, extrahepatic metastasis; * 3\. At least one measurable liver metastasis by RECIST criteria. No more than 5 lesions and smaller than 4.0 cm each; * 4\. Patients' liver function classified as Child-Pugh A or B, total bilirubin \<=3.0 mg/dL, serum creatinine \<= 2.5 mg/dL, White blood cell count \>= 2.0×10\^9/L, Platelets \>= 100×10\^9/L; * 5\. Performance Status(PS): Eastern cooperative Oncology Group (ECOG) \<= 2, and life expectancy longer than three months; * 6\. Prior therapy, e.g., chemotherapy, radiation, is allowed provided that more than one month washout time is given, and recover from the previous treatment: according to the Common Terminology Criteria Adverse Events (CTC AE) version 4.0, all side effects (except for hair loss) degrading to 1 level or lower.
Exclusion criteria
* 1\. Child-Pugh grade Class C, or tumor invasion into the portal vein; * 2\. Patient underwent previous cryoablation or other thermal ablation; * 3\. Patient underwent prior therapy, e.g., chemotherapy, radiation,or other anti-cancer medication no more than 3 weeks; * 4\. Patients with severe disorders of heart, lung, liver, kidney function or irreversible coagulation disorder; * 5\. Patients combined with other uncontrolled disease, including but not limited to: hypertension or diabetes, active infection, or mental illness or social condition that may affect the subject's compliance; * 6\. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Local control rate | From date of randomization until the date of progression of ablation lesion, assessed up to 5 years. | Contrast enhanced CT or MRI was performed to evaluate Local tumor control |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | From date of randomization until the date of death, assessed up to 5 years. | Overall survival is defined as the time (in months) from the date of randomization to the death date. |
| Progression free survival (PFS) | From date of randomization until the date of first documented progression, recurrence or date of death from any cause, whichever came first first documented progression or date of death from any cause, whichever came first, assessed up to 5 years. | Progression-free survival is defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. |
| Complication rate | 6 months | Number of participants with adverse events and complication |
Countries
China
Contacts
Primary ContactXudong Qu, MD. PhD.
Backup ContactWentao Li, MD. PhD.
Outcome results
None listed